Facial Aging Science: What 2025 Research Shows

Key Takeaways

• Perimenopause triggers measurable losses in facial fat, bone, and collagen that go beyond surface wrinkles, according to a 2025 review in Facial Plastic Surgery & Aesthetic Medicine (PMID 42614013).
• A 40.68 MHz radiofrequency device showed high patient-reported satisfaction for skin tightening in a real-world retrospective study published in Lasers in Medical Science (PMID 42611337).
• Combining microfocused ultrasound with a 1550-nm fractional laser produced better skin texture results than either device alone in a split-face trial of Asian patients (PMID 42587095).
• A thermally processed PRP-based biofiller called ExoFiller is in early clinical use as a volumizing agent, with preliminary results reported in Facial Plastic Surgery (PMID 42633752).
• Platelet-derived nanovesicles carrying collagen III mRNA improved skin collagen in preclinical models, though human trials have not yet been conducted (PMID 42612849).

How does perimenopause change the structure of the face?

Perimenopause reshapes the face through a cascade of hormonal changes that facial aging science has now mapped in considerable detail — estrogen loss drives simultaneous breakdown across skin, fat, and bone, so the changes compound each other rather than occurring in isolation. Multiple processes unfold at once.

Estrogen receptors are present throughout facial tissue, and as estrogen levels drop during perimenopause, a comprehensive clinical review documents the following structural changes:

• Skin thinning and collagen loss. Skin loses roughly 30% of its collagen in the first five years after menopause begins. The dermis thins, surface texture roughens, and the skin's ability to retain water drops sharply — all of which make fine lines appear faster and deeper than they would from chronological aging alone.
• Fat compartment redistribution. Facial fat does not simply disappear uniformly. The fat pads of the cheeks, temples, and under-eye area deflate and shift downward, while fat can accumulate along the jaw and neck. The result is a face that looks simultaneously hollowed in the midface and heavier at the lower third.
• Bone resorption. The facial skeleton itself shrinks. The jaw and eye socket lose volume, reducing the scaffolding that holds soft tissue in place. Skin and fat that once sat over a fuller bony structure now have less support, which accelerates sagging.
• Reduced skin elasticity. A multimodal ultrasound study measuring skin characteristics in adult women found measurable reductions in dermal density and elasticity that correlate with hormonal aging — changes visible on imaging before they are obvious to the naked eye.

The compounding effect matters for anyone considering treatment. A provider who addresses only surface texture while ignoring volume loss, or who adds filler without accounting for bone resorption, is working with an incomplete picture of what perimenopause actually does to the face. The comprehensive review makes the case that perimenopausal facial changes require a layered approach — one that accounts for skin quality, fat distribution, and skeletal support together — because each layer influences how the others look and respond to treatment.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before pursuing any aesthetic or medical treatment.

What does ultrasound imaging reveal about how facial skin varies by age?

Ultrasound imaging reveals clear, measurable differences in facial skin across age groups. High-frequency ultrasound maps skin layer by layer, showing exactly how thickness, density, and structural organization shift over decades.

A multimodal ultrasound study of Chinese adult females found that both the epidermis and dermis thin measurably with age. The dermis showed the more dramatic change: dermal thickness dropped significantly in older age groups compared to younger ones, and dermal echogenicity — a measure of how densely packed and organized the collagen fibers are — declined in parallel. Looser, less organized collagen scatters ultrasound waves differently than healthy, dense collagen does, so the imaging picks up structural degradation that no mirror can show.

The research documented three key patterns. Dermal thinning progresses across age groups, with older women showing measurably thinner dermis than younger women at the same facial sites. Echogenicity loss reflects collagen disorganization — the dermis becomes less acoustically dense as collagen fibers break down and the matrix loosens. Different facial zones age at different rates, which is why ultrasound mapping is more informative than a single measurement.

Hormonal shifts accelerate some of these changes. Research on perimenopausal facial aging documents that estrogen decline speeds collagen loss and reduces skin hydration, compressing years of gradual change into a relatively short window around menopause. Ultrasound can detect the resulting dermal thinning even before it becomes visible as sagging or deep lines.

Baseline ultrasound measurements give clinicians an objective starting point for evaluating treatment claims. A treatment that claims to stimulate collagen can be measured against actual post-treatment dermal thickness data rather than patient impressions alone. Without that baseline, it's genuinely hard to separate real structural change from temporary swelling or placebo effect.

Skin that looks similar on the surface can differ substantially in dermal depth and density. Two people the same age may have very different ultrasound profiles depending on sun exposure history, genetics, and hormonal status. Population-level ultrasound data, like the findings above, helps set realistic expectations for what any given treatment can achieve.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any decisions about aesthetic or medical treatments.

Which energy-based devices does 2025 research support for skin tightening?

The 2025 research on energy-based devices for skin tightening points most clearly to two technologies: high-frequency radiofrequency and microfocused ultrasound. Both rest on clinical trial data, not manufacturer claims alone.

Radiofrequency at 40.68 MHz

A retrospective real-world study published in 2025 tracked patient-reported outcomes after treatment with a 40.68 MHz radiofrequency device. The study found high satisfaction rates, with patients reporting visible skin tightening and improved texture. The frequency matters: 40.68 MHz delivers energy more superficially than older RF platforms, targeting the dermis without the deep heating that carries higher discomfort and downtime.

Microfocused Ultrasound (MFU)

A prospective, randomized split-face trial tested microfocused ultrasound combined with a 1550-nm non-ablative fractional laser in Asian patients with Fitzpatrick skin types III–IV — a group historically underrepresented in aesthetic research. That trial found the combination produced greater improvements in skin laxity and texture than either device alone, with a favorable safety profile across darker skin tones. MFU works by delivering focused acoustic energy to the superficial musculoaponeurotic system (SMAS) layer, triggering collagen remodeling at depths that topical products and surface-level lasers cannot reach.

What the evidence shows:

Neither device produces permanent results. Collagen remodeling continues for roughly three to six months after treatment, and maintenance sessions are typically needed annually. Combination protocols — MFU paired with fractional laser — outperformed single-device treatment in the split-face trial, which matters if a medspa quotes you a package. Skin type affects device selection. The 2025 MFU trial specifically validated safety in Fitzpatrick III–IV skin, where some laser-based tightening approaches carry higher risk of post-inflammatory hyperpigmentation. Ultrasound imaging of skin layers is increasingly used to plan and assess treatment. A 2025 multimodal ultrasound study quantified dermal thickness and density in adult women, showing how much structural variation exists between individuals — a reminder that a device protocol built for one skin profile may not translate directly to another.

Infrared laser irradiation appears in 2025 research, though primarily in combination with photodynamic therapy for rejuvenation rather than as a standalone tightening device. That pilot study focused on texture and tone rather than laxity, so the evidence base for infrared as a tightening tool remains thinner than for RF or MFU.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before pursuing any aesthetic procedure.

What is ExoFiller and how does it differ from standard PRP?

ExoFiller is a thermally processed platelet-rich plasma concentrate designed as a biofiller. It differs from standard PRP by adding a heat-reconstruction step that transforms liquid plasma into a gel-like material holding its shape under the skin. The two products share the same raw ingredient but behave very differently once injected.

Standard PRP starts with a blood draw. A centrifuge separates the platelet-rich plasma from red blood cells, and the clinician injects the liquid directly into the skin or scalp. Platelets release growth factors—PDGF, TGF-β, VEGF—that signal surrounding cells to produce collagen and new blood vessels. The liquid disperses quickly, which limits its ability to add volume.

ExoFiller takes that same platelet-rich plasma and applies controlled heat to denature the proteins, creating a semi-solid concentrate. According to a 2025 development and clinical study, this thermal reconstruction produces a biofiller that retains the bioactive growth factors of PRP while gaining enough structural integrity to act as a soft-tissue filler—something liquid PRP cannot do.

The practical differences:

Volume effect. Standard PRP adds minimal volume. ExoFiller gels and can fill fine lines and shallow depressions the way a hyaluronic acid filler does, while also delivering the biological signaling of PRP.

Longevity. The same clinical study reports that ExoFiller maintained measurable volume and skin quality improvements at follow-up assessments, though long-term durability data beyond the study window remains limited.

Safety profile. Because ExoFiller is made from the patient's own blood, the risk of allergic reaction or foreign-body response is low—the same advantage standard PRP already carries.

Processing time. The thermal step adds preparation time compared to standard PRP, meaning the in-clinic procedure takes longer.

ExoFiller is newer than standard PRP, which has decades of published data behind it. The clinical evidence for ExoFiller is promising but still early-stage. Patients who want volume correction alongside the regenerative effects of PRP have a biologically plausible reason to ask about it—and a good reason to ask their provider how many ExoFiller cases they have personally performed.

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before pursuing any aesthetic procedure.

Can mRNA technology rebuild lost collagen in skin?

mRNA technology can rebuild lost collagen in skin — at least in early-stage research. A platelet-derived nanoparticle system delivering collagen III mRNA has shown measurable collagen production in preclinical models, though human clinical data remain limited. This approach works differently from lasers or fillers: instead of stimulating existing cells indirectly, it delivers genetic instructions that tell skin cells to manufacture a specific collagen type themselves.

A 2025 study published on PubMed (PMID 42612849) tested a hybrid delivery system — platelet-derived nanovesicles fused with lipid nanoparticles — loaded with collagen III mRNA. The system was designed to penetrate the skin barrier and transfect fibroblasts, the cells responsible for collagen synthesis. Treated skin showed increased collagen III expression and improved skin thickness compared to controls.

Several constraints shape where this technology stands now:

The delivery problem is real. mRNA degrades quickly and doesn't cross skin easily. The nanovesicle-LNP hybrid in the PMID 42612849 study was engineered specifically to solve that — the platelet-derived outer shell helps the particle evade immune clearance and reach fibroblasts in the dermis.

Collagen III matters. It's a major structural protein in young skin. Separate research confirms that collagen density measurably declines with age, particularly around perimenopause, when hormonal shifts accelerate dermal thinning — a pattern documented in PMID 42614013.

Human trials are early. The collagen III mRNA work is preclinical. No large randomized controlled trials in humans have been published yet. That gap matters enormously when comparing this to established treatments like radiofrequency or fractional laser, which have years of human outcome data behind them.

Duration is unknown. Because mRNA is transient by design — it doesn't integrate into DNA — repeated treatments would likely be necessary to sustain collagen levels. How often, and at what dose, remains an open question.

The science is credible and the mechanism is sound. Skin cells can, in principle, be instructed to produce collagen they've stopped making. Getting that instruction reliably into the right cells, at therapeutic levels, without triggering inflammation — that's the engineering challenge still being worked out. Expect to see this in clinical trials before it reaches a medspa treatment menu.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any decisions about aesthetic or medical treatments.

What does photodynamic therapy do for facial rejuvenation?

Photodynamic therapy for facial rejuvenation works by using a light-activated chemical to selectively damage aged or sun-damaged skin cells, prompting the skin to rebuild collagen and clear pigmentation. A photosensitizing agent—most commonly aminolevulinic acid (ALA) or methyl aminolevulinate (MAL)—is applied to the skin, absorbed preferentially by abnormal cells, then activated by a specific wavelength of light to generate reactive oxygen species that destroy those cells.

A 2025 pilot study published in a peer-reviewed journal tested both ALA and MAL combined with amber LED and infrared laser irradiation across multiple treatment sessions. That study found improvements in skin texture, tone, and fine lines, with both photosensitizers producing measurable results—though the researchers noted differences in tolerability and response between the two agents.

PDT addresses these concerns most effectively:

Pigmentation and sun damage. The reactive oxygen generated during treatment targets melanin-rich and dysplastic cells more aggressively than surrounding healthy tissue.

Fine lines and skin texture. Collagen remodeling follows the controlled injury; the pilot study documented texture improvement across participants.

Actinic keratoses. PDT has a longer track record here than in cosmetic rejuvenation, and the mechanism is identical.

PDT cannot reverse deep structural volume loss, significant laxity, or the kind of dermal thinning that accelerates during perimenopause. Perimenopause involves hormonal changes to collagen density that light-based treatments alone cannot address, as research on perimenopausal facial aging makes clear.

Durability remains uncertain. The pilot study was short-term, and the researchers themselves described it as preliminary. PDT results are not permanent—sun exposure, continued aging, and skin type all affect how long improvements last. Fitzpatrick skin types III and IV require particular attention to photosensitizer selection and light dosing, since higher melanin content raises the risk of post-inflammatory hyperpigmentation.

Downtime is real. Treated skin is photosensitive for 24–48 hours post-procedure, and redness, peeling, and swelling are common for several days. Anyone considering PDT should discuss their skin type, medication list, and sun exposure habits with a licensed dermatologist or physician before scheduling a session.

---

This content is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before making any decisions about cosmetic or medical procedures.

FAQ

What is facial aging science telling us about hormones and skin?

Facial aging science now links the perimenopause transition to specific structural losses—including reduced facial fat compartments, decreased bone density, and lower collagen production—not just surface-level wrinkling. A 2025 review in Facial Plastic Surgery & Aesthetic Medicine (PMID 42614013) outlines how estrogen decline accelerates these changes. Providers who understand this can tailor treatment timing and type more precisely.

How accurate is ultrasound for measuring facial skin thickness?

A 2025 multimodal ultrasound study of Chinese adult females (PMID 42618384) found that high-frequency ultrasound can reliably quantify skin layer thickness and density across different facial zones and age groups. The data showed measurable thinning of the dermis with advancing age. Clinicians use these measurements to track treatment response and set realistic expectations.

Is 40.68 MHz radiofrequency safe and effective for skin tightening?

A retrospective real-world study published in Lasers in Medical Science (PMID 42611337) reported high patient satisfaction scores for a 40.68 MHz radiofrequency device used for skin tightening. The study was retrospective and self-reported, so it cannot establish efficacy the way a randomized controlled trial would. Consult a qualified provider to determine whether this device suits your skin type and goals.

What happens when microfocused ultrasound and fractional laser are combined?

A prospective split-face randomized trial in Asian patients with Fitzpatrick skin types III–IV (PMID 42587095) found that the combination of microfocused ultrasound and a 1550-nm non-ablative fractional laser outperformed either treatment alone for skin texture and laxity. Side effects were manageable and consistent with each device used separately. Results may vary by skin type, age, and baseline laxity.

What is ExoFiller and is it available widely?

ExoFiller is a thermally reconstructed platelet-rich plasma concentrate processed into a gel-like biofiller intended for facial volume restoration. Early clinical application data were published in Facial Plastic Surgery (PMID 42633752), but the product is not yet widely available and remains in early-stage clinical use. Ask a board-certified provider whether it is offered at their practice and what the current evidence base looks like.

Does mRNA therapy for collagen work in humans yet?

As of the studies reviewed here, collagen III mRNA delivered via platelet-derived nanovesicles has shown promising results only in preclinical (laboratory and animal) models (PMID 42612849). No human clinical trial data were reported in this study. The technology is experimental and not currently available as a standard medspa treatment.

How does photodynamic therapy compare when using ALA versus MAL for facial rejuvenation?

A pilot study published in the Journal of Biophotonics (PMID 42575720) compared aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) combined with amber LED and infrared laser for facial rejuvenation. Both photosensitizers produced skin improvements, with some differences in tolerability and response noted between the two. Because this was a small pilot study, larger trials are needed before drawing firm conclusions.

Should I combine neck and face treatments at the same appointment?

A 2025 exploratory study in the Journal of Clinical Medicine (PMID 42590155) evaluated a combined calcium hydroxyapatite, hyaluronic acid, and botulinum toxin A protocol for neck rejuvenation and found encouraging early results. Whether combining neck and face treatments in one session is appropriate depends on your anatomy, the products used, and your provider's clinical judgment. Always discuss sequencing and recovery with a qualified injector before booking.

This article is for general information and is not medical advice. Aesthetic treatment results vary by individual -- consult a licensed, qualified provider before pursuing any cosmetic procedure.